Price T Rowe Associates Inc Theseus Pharmaceuticals, Inc. Transaction History

Price T Rowe Associates Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$2.66 - $10.04 $105,093 - $396,670	-39,509 Reduced 3.15%	1,216,500 $3.27 Million
Q2 2023 Aug 14, 2023	SELL	$7.28 - $11.82 $506,367 - $822,151	-69,556 Reduced 5.25%	1,256,009 $11.7 Million
Q1 2023 May 15, 2023	BUY	$5.21 - $14.05 $60,732 - $163,780	11,657 Added 0.89%	1,325,565 $11.8 Million
Q4 2022 Feb 14, 2023	SELL	$4.69 - $8.36 $316,954 - $564,977	-67,581 Reduced 4.89%	1,313,908 $6.54 Million
Q3 2022 Nov 14, 2022	SELL	$5.7 - $8.68 $21,625 - $32,931	-3,794 Reduced 0.27%	1,381,489 $8.01 Million

Q2 2022 Aug 15, 2022	SELL	$5.04 - $14.05 $258,718 - $721,228	-51,333 Reduced 3.57%	1,385,283 $7.66 Million
Q1 2022 May 16, 2022	BUY	$8.75 - $14.51 $1.2 Million - $1.99 Million	137,129 Added 10.55%	1,436,616 $16.3 Million
Q4 2021 Feb 14, 2022	BUY	$8.98 - $20.09 $11.7 Million - $26.1 Million	1,299,487 New	1,299,487 $16.2 Million

1.06M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.